Skip to main content
. Author manuscript; available in PMC: 2011 Feb 1.
Published in final edited form as: Neuropharmacology. 2009 Nov 1;58(2):330. doi: 10.1016/j.neuropharm.2009.10.009

Figure 2.

Figure 2

BDNF protection against PCP-induced neurotoxicity is mediated by activation of PI-3K/Akt and ERK pathways. Inhibition of activation of PI-3K by LY294002 (30 μM) (A), Akt by TCN (10 μM) (B), or ERK by PD98059 (30 μM) (C) each attenuated BDNF protection against PCP neurotoxicity. Each inhibitor was added 1 h before BDNF (50 ng/ml). PCP (3 μM) was added 1 h after BDNF. Slices were collected 12 h after PCP treatment. N=6. *: p< 0.05, vs control (no treatment); # p<0.05 vs PCP; ^: p<0.05, vs PCP+BDNF; &: p<0.05, vs kinase inhibitors alone (one-way ANOVA).